Partnership will accelerate development of superior oncology
agents to benefit patients
SCOTTSDALE, Ariz. - Jan. 7, 2011 - TGen Drug Development (TD2) and
Oncoholdings Inc. announced today a partnership agreement that
could lead to the prompt development of new anti-cancer
agents.
Oncoholdings Inc. is a Syracuse, N.Y.-based pharmaceutical company
focused on acquiring and developing the most promising preclinical
and early clinical anti-cancer agents. It was founded by some of
the world's leading oncology scientists and leverages the unique
insights and experiences of its founders and world-class scientific
advisory board.
TD2, based in Scottsdale, Ariz., provides drug development firms
with expertise in moving promising laboratory discoveries through
the pre-clinical, clinical and regulatory approval steps of getting
new drugs to patients as quickly and safely as possible.
Under the agreement announced today, TD2 - a subsidiary of
the Phoenix-based Translational Genomics Research Institute (TGen)
- will be the exclusive development partner for Oncoholdings'
oncology portfolio. The company plans to develop as many as 15
early-stage drugs over the next three years.
"We are extremely eager to put the scientific assets of
Oncoholdings on the most expeditious and precise path, moving their
drug compounds safely and effectively to benefit cancer patients
who so desperately need better treatments," said Dr. Stephen
Gately, President of TD2 and a member of the Scientific Advisory
Board of Oncoholdings.
Oncoholdings specifically targets drug candidates for development
with the potential to:
- Demonstrate superiority over standard-of-care in pre-clinical or early human trials.
- Address significant unmet medical needs in oncology.
- Leverage Oncoholdings' significant expertise in cancer trial design and execution.
"Through our partnership with TGen Drug Development we are
confident that we have secured a team comprised of the of the
world's top scientists and researchers to develop Oncoholdings'
drug portfolio," said Dr. Jeffrey Evans, founder and Chief
Executive Officer of Oncoholdings.
"TD2's vast knowledge and experience developing cancer therapies is
important to Oncoholdings, as we are positioned to advance more
than a dozen compounds with various mechanisms of action. We are
very pleased to have found a partner that can meet the challenges
of rapidly and effectively progressing our strategy," said Dr.
Evans, who also is the former co-founder and President of Rondaxe,
a leading pharmaceutical consultancy.
Oncoholdings expects to announce the acquisition of its first group
of products in the first quarter of 2011. Among these first
products is a novel first-in-class therapy, as well as products
with clearly superior efficacy and safety profiles relative to
existing therapeutics. Those interested in discussing opportunities
with Oncoholdings are encouraged to contact Dr. Evans at:
[email protected]
About Oncoholdings
Oncoholdings, Inc., is a pharmaceutical company focused on
acquiring and developing the most promising preclinical and early
clinical anti-cancer agents. Oncoholdings was founded by some of
the world's leading oncology scientists and leverages the unique
insights and experiences of its founders and world-class scientific
advisory board. For more information, visit:
www.oncoholdings.com.
Press Contact:
Susan Falk
414.232.2562
[email protected]
*
About TD2
TGen Drug Development (TD2), a wholly owned subsidiary of the
Translational Genomics Research Institute (TGen), is a 501(c) 3
non-profit organization. TD2 provides innovative services for
oncology-focused biopharmaceutical companies using a dedicated team
of professionals with broad experience and understanding in drug
development. TD2 is uniquely positioned to support the need for
improved and accelerated development of new chemical entities
(NCE's) for life-threatening diseases. TD2 uses a unique
combination of experience gained through its contract research
organization business, and an integrated suite of proprietary and
non-proprietary tools, preclinical study execution, regulatory
affairs assistance, clinical trial design and management, and drug
development experts to successfully move therapeutics towards
regulatory approval. TD2 is dedicated to reducing the risks and
uncertainty inherent in the drug development process. For more
information, visit: www.td2.org.
*
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix,
Arizona-based non-profit organization dedicated to conducting
groundbreaking research with life changing results. Research at
TGen is focused on helping patients with diseases such as cancer,
neurological disorders and diabetes. TGen is on the cutting edge of
translational research where investigators are able to unravel the
genetic components of common and complex diseases. Working with
collaborators in the scientific and medical communities, TGen
believes it can make a substantial contribution to the efficiency
and effectiveness of the translational process. TGen is affiliated
with the Van Andel Research Institute in Grand Rapids, Michigan.
For more information, visit: www.tgen.org.
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]
